Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

Drug Discovery Today

Volumn 17, Issue 9-10, 2012, Pages 419-424

  Morgan, Paul ^a   Van Der Graaf, Piet H ^a   Arrowsmith, John ^a   Feltner, Doug E ^a   Drummond, Kira S ^a   Wegner, Craig D ^a   Street, Steve D A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; ARIPIPRAZOLE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; DOPAMINE 3 RECEPTOR STIMULATING AGENT; MARAVIROC; OXYCODONE; PF 592379; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SILDENAFIL;

BRADYCARDIA; CLINICAL DEVELOPMENT PLAN; CLINICAL PHARMACOLOGY; DECISION MAKING; DIZZINESS; DRUG ACTIVITY; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; ERECTILE DYSFUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PARKINSON DISEASE; PHARMACOKINETICS; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STUDY DESIGN; SWEATING; SYNCOPE; TREATMENT FAILURE; VOMITING;

EID: 84860690620     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.12.020     Document Type: Short Survey

References (26)

1. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
2. J. Arrowsmith Phase III and submission failures: 2007-2010 Nat. Rev. Drug Discov. 10 2011 87
3. J.A. DiMasi Trends in risks associated with new drug development: success rates for investigational drugs Clin. Pharmacol. Ther. 87 2010 272 277
4. J. Arrowsmith Phase II failures: 2008-2010 Nat. Rev. Drug Discov. 10 2011 328
5. S.M. Paul How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
6. M. Wehling Assessing the translatability of drug projects: what needs to be scored to predict success? Nat. Rev. Drug Discov. 8 2009 541 546
7. M. Rowland Physiologically-based pharmacokinetics in drug development and regulatory science Annu. Rev. Pharmacol. Toxicol. 51 2011 45 73
8. 1 receptors in vitro and in vivo Br. J. Pharmacol. 164 2011 992 1007
9. E. Dula Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction Eur. Urol. 39 2001 558 563
10. D. Hepworth Optimization of oral pharmacokinetics in the discovery of clinical candidates for the treatment of sexual dysfunction Abstracts of Papers, 237th ACS National Meeting March 22-26, 2009, Salt Lake City, UT, USA 2009 http://www.acsmedchem.org/mediabstracts2009.pdf
11. N. Attkins Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog and human Xenobiotica 40 2010 730 742
12. P.H. Van der Graaf, and N. Benson Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development Pharm. Res. 28 2011 1460 1464
13. T. Dragic HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 Nature 381 1996 667 673
14. R. Liu Homozygous defect in HIV-1 coreceptor accounts for resistance of some multi-exposed individuals to HIV-1 infection Cell 86 1996 367 377
15. K.J. Pasi The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia Br. J. Haematol. 111 2000 136 142
16. E.A. Berger Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism and disease Annu. Rev. Immunol. 17 1999 657 700
17. J.M. Strizki SCH-C (SCH 351125) an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo Proc. Natl. Acad. Sci. U. S. A. 98 2001 12718 12723
18. P. Dorr Maraviroc (UK-427,857), a potent, orally bioavailable and selective small molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 49 2005 4721 4732
19. D.K. Walker Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV Drug Metab. Dispos. 33 2005 587 595
20. S. Bonhoeffer Virus dynamics and drug therapy Proc. Natl. Acad. Sci. U. S. A. 271 1997 1582 1585
21. M.C. Rosario Pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc Clin. Pharmacol. Ther. 78 2005 508 519
22. M.C. Rosario Pharmacokinetic-pharmacodynamic model to optimise the Phase IIa development program of maraviroc J. Acquir. Immune Defic. Syndr. 42 2006 183 191
23. J. Gabrielsson Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry Curr. Top. Med. Chem. 11 2011 404 418
24. J.R. Empfield, and P.D. Leeson Lessons learned from candidate drug attrition IDrugs 13 2010 869 873
25. M.E. Cartwright Proof of concept: a PhRMA position paper with recommendations for best practice Clin. Pharmacol. Ther. 87 2010 278 285
26. A. Cohen Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development-designing informative human pharmacological studies Clin. Pharmacokinet. 47 2008 373 381